Histone deacetylase inhibitors: anticancer compounds - PubMed (original) (raw)
Review
Histone deacetylase inhibitors: anticancer compounds
Karen T Smith et al. Int J Biochem Cell Biol. 2009 Jan.
Abstract
The reversible acetylation of proteins is mediated by histone acetyltransferases which acetylate proteins and histone deacetylases that remove the acetyl groups. High levels of histone acetylation are correlated with active genes, while hypoacetylation of histones corresponds with gene repression. Importantly, acetylation also occurs on non-histone proteins and this can affect the activity and stability of these proteins. Aberrant epigenetic changes are a common hallmark of tumors and imbalances in the activities of deacetylases have been associated with cancers. Accordingly, inhibitors to the histone deacetylases are in clinical trials for the treatment of several cancer types. These drugs mediate a number of molecular changes and in turn can induce cell cycle arrest, apoptosis or differentiation of cancer cells while displaying limited toxicity in normal cells.
Similar articles
- Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Konstantinopoulos PA, et al. Expert Opin Investig Drugs. 2007 May;16(5):569-71. doi: 10.1517/13543784.16.5.569. Expert Opin Investig Drugs. 2007. PMID: 17461732 Review. - Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M, Shimazu T, Matsuyama A. Yoshida M, et al. Prog Cell Cycle Res. 2003;5:269-78. Prog Cell Cycle Res. 2003. PMID: 14593721 Review. - Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT, Bernards R. Epping MT, et al. Int J Biochem Cell Biol. 2009 Jan;41(1):16-20. doi: 10.1016/j.biocel.2008.07.020. Epub 2008 Aug 12. Int J Biochem Cell Biol. 2009. PMID: 18765293 Review. - Anticancer activities of histone deacetylase inhibitors.
Bolden JE, Peart MJ, Johnstone RW. Bolden JE, et al. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133. Nat Rev Drug Discov. 2006. PMID: 16955068 Review. - Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Mai A, et al. Med Res Rev. 2005 May;25(3):261-309. doi: 10.1002/med.20024. Med Res Rev. 2005. PMID: 15717297 Review.
Cited by
- Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.
Marks PA. Marks PA. Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):717-25. doi: 10.1016/j.bbagrm.2010.05.008. Epub 2010 Jun 8. Biochim Biophys Acta. 2010. PMID: 20594930 Free PMC article. Review. - Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.
Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, Jackson SP. Miller KM, et al. Nat Struct Mol Biol. 2010 Sep;17(9):1144-51. doi: 10.1038/nsmb.1899. Epub 2010 Aug 29. Nat Struct Mol Biol. 2010. PMID: 20802485 Free PMC article. - Targeted therapy in the treatment of malignant gliomas.
Lukas RV, Boire A, Nicholas MK. Lukas RV, et al. Onco Targets Ther. 2009 Feb 18;2:115-33. doi: 10.2147/ott.s3027. Onco Targets Ther. 2009. PMID: 20616900 Free PMC article. - Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z. Yang C, et al. Anticancer Res. 2011 Apr;31(4):1115-23. Anticancer Res. 2011. PMID: 21508354 Free PMC article. - Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest.
Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Koprinarova M, et al. BMC Mol Biol. 2010 Jun 24;11:49. doi: 10.1186/1471-2199-11-49. BMC Mol Biol. 2010. PMID: 20576112 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources